)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Orchestra BioMed
Orchestra BioMed (OBIO) investor relations material
Orchestra BioMed Wells Fargo 21st Annual Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Wells Fargo 21st Annual Healthcare Conference summary10 Sep, 2026
Business model and partnerships
Focuses on innovation, IP, and clinical execution, leveraging risk/reward partnerships with major medical device companies for commercialization and global market access.
Strategic partners include Medtronic and Terumo, with significant investments and royalty-sharing agreements; Ligand and other healthcare investors also hold stakes.
Partnerships insulate partners from R&D burdens while providing growth programs and shared upside.
Over 21% of the company is owned by strategic investors, ensuring alignment and long-term support.
Near-term catalysts are fully funded through 2027, positioning the company for value creation.
AVIM therapy program
AVIM therapy targets hypertension in pacemaker patients, leveraging existing devices for immediate and sustained blood pressure reduction.
The pivotal BACKBEAT trial is nearing enrollment completion, with primary data expected in Q2 next year and potential U.S. commercialization in H1 2028.
Medtronic partnership includes exclusive rights, regulatory, manufacturing, and sales responsibilities, with uncapped royalties starting at $500 per device.
Pilot studies show consistent >10 mmHg systolic BP reduction, improved cardiac function, and better compliance due to always-on therapy.
Two Breakthrough Device designations and a potential $16 billion global market opportunity beyond the pacemaker population.
Virtue SAB program and coronary market
Virtue SAB delivers sirolimus via a proprietary AngioInfusion Balloon, addressing the shift to leave-nothing-behind coronary interventions.
Targets a $7.5 billion PCI market, with at least half transitioning to drug-eluting or drug-coated balloons.
Demonstrates superior drug delivery and retention compared to leading stents and balloons, with promising pilot study results versus Boston Scientific's AGENT balloon.
IDE pivotal trial underway, aiming for non-inferiority and potential superiority to AGENT; Terumo holds right of first refusal for coronary rights.
Precedent transactions in the space suggest significant potential value for the program.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Orchestra BioMed
- Net loss rose to $44.4M as pivotal trials advanced and cash runway extended into Q4 2027.OBIO
Q2 2026 - Strategic financing fuels pivotal AVIM trial and advances Virtue's sirolimus drug delivery innovation.OBIOPiper Sandler 37th Annual Healthcare Conference
- All proposals passed, directors re-elected, and annual compensation vote frequency set.OBIOAGM 2026
- Pivotal cardiovascular device trials progress with strong partners and funding, targeting 2028 launches.OBIOSidoti Small-Cap Virtual Investor Conference
- 2026 Employee Stock Purchase Plan approved, enabling employees to acquire up to 750,000 shares.OBIOProxy filing
- Upcoming BackBeat and Virtue trial milestones signal strong growth and partnership-driven value.OBIOJefferies Global Healthcare Conference 2026
- Pivotal cardiovascular therapies advance toward commercialization with strong partner support.OBIOCorporate presentation
- Net loss widened to $20.7M as R&D spending rose, with cash runway into Q4 2027 and new FDA designation.OBIOQ1 2026
- Board recommends approval of all annual meeting proposals, including compensation and governance.OBIOProxy filing
Next Orchestra BioMed earnings date
Q3 202610 Nov, 2026
Orchestra BioMed
Next Orchestra BioMed earnings date
Q3 202610 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Orchestra BioMed Holdings, Inc. is a biomedical innovation company focused on accelerating the development and commercialization of high-impact medical technologies. The company operates through a partnership-enabled business model, collaborating with leading medical device companies to bring its innovations to market. Its key product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT), which is designed to treat hypertension in patients with pacemakers, and Virtue Sirolimus AngioInfusion Balloon (SAB), intended for the treatment of atherosclerotic artery disease. Orchestra BioMed has strategic partnerships with companies like Medtronic and Terumo Corporation to advance the development and global commercialization of these products. The company is headquartered in New Hope, Pennsylvania, and its shares are listed on the Nasdaq.